


Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01

Merck Serono  
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas


11DEC2014 00:01



Merck Serono  
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas


11DEC2014 00:01



Merck Serono  
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01






Merck Serono  
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: .



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01




Levothyroxine  
EMR 200125-001

Merck Serono  
EMR 200125-001

Page 37 of 216  
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number: .



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01




**Levothyroxine  
EMR 200125-001**

Merck Serono  
EMR 200125-001

Page 41 of 216  
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
 Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
 Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
 Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
 15.4.2.10.sas


11DEC2014 00:01



Merck Serono  
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01






Merck Serono  
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number: 11...



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas


11DEC2014 00:01



Merck Serono  
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014\_00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01

Merck Serono  
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: \*



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number: J



@: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TPL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas


11DEC2014 00:01



Merck Serono  
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas


11DEC2014 00:01



Merck Serono  
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/Figure 15.4.2.10.sas

11DEC2014 00:01






Merck Serono  
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: [REDACTED]




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/Figure  
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas


11DEC2014 00:01



Merck Serono  
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: :



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas


11DEC2014 00:01



Merck Serono  
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas


11DEC2014 00:01

**Levothyroxine  
EMR 200125-001**

Merck Serono  
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
 Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
 Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
 Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
 15.4.2.10.sas

11DEC2014 00:01






Merck Serono  
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number: J



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: --




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas


11DEC2014 00:01



Merck Serono  
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01




Merck Serono  
EMR 200125-001

Page 73 of 216  
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.3.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01




Levothyroxine  
EMR 200125-001

Merck Serono  
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number: 7 1175



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
 Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
 Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
 Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
 15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas


11DEC2014 00:01



Merck Serono  
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/Figure 15.4.2.10.sas


11DEC2014 00:01



Merck Serono  
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number: 101126



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01






Merck Serono  
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TEL programs/figures/figure  
15.4.2.10.sas


11DEC2014 00:01



Merck Serono  
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_marc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas


11DEC2014 00:01



Merck Serono  
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas


11DEC2014 00:01



Merck Serono  
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01






Merck Serono  
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas


11DEC2014 00:01



Merck Serono  
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas


11DEC2014 00:01



Merck Serono  
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas


11DEC2014 00:01



Merck Serono  
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01






Merck Serono  
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01

Levothyroxine  
EMR 200125-001


Bioequiv EMR200125-001 Page 1074 of 1628 alation vs. old formulation

Merck Serono  
EMR 200125-001

Page 101 of 216  
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/Figure  
15.4.2.10.sas


11DEC2014 00:01



Merck Serono  
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL\_programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
 Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
 Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
 Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
 15.4.2.10.sas

11DEC2014 00:01






Merck Serono  
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: J 10000



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 6




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL\_programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/Figure  
15.4.2.10.sas

11DEC2014 00:01

Merck Serono  
EMR 200125-001  
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing.16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



0: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1 000



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01






Merck Serono  
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: --




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01

Merck Serono  
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014\_00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas


11DEC2014 00:01



Merck Serono  
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/Figure  
15.4.2.10.sas

11DEC2014 00:01

Merck Serono  
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01






Merck Serono  
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: J



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/Figure  
15.4.2.10.sas

11DEC2014 00:01